Free first page
© 2020 by American Society of Clinical Oncology

Conception and design: Preetesh Jain, Michael Wang

Collection and assembly of data: All authors

Data analysis and interpretation: All authors

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to or

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Martin Dreyling

Consulting or Advisory Role: Acerta Pharma/AstraZeneca, Bayer/Vital, Celgene/Jazz, Gilead Sciences, Janssen-Cilag, Novartis, Roche, Beigene

Speakers' Bureau: Bayer Health, Celgene, Gilead Sciences, Janssen-Cilag, Roche Pharma AG

Research Funding: Celgene (Inst), Janssen-Cilag (Inst), Roche Pharma AG (Inst), AbbVie (Inst)

Travel, Accommodations, Expenses: Celgene, Janssen-Cilag, Roche Pharma AG

John F. Seymour

Honoraria: AbbVie, Acerta Pharma, Janssen, Roche, Sunesis Pharmaceuticals, Takeda

Consulting or Advisory Role: AbbVie, Acerta Pharma, Janssen, Roche, Sunesis Pharmaceuticals, Takeda, AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, MEI Pharma, MorphoSys

Speakers' Bureau: AbbVie, Roche

Research Funding: AbbVie, Celgene, Janssen, Roche

Expert Testimony: Roche

Travel, Accommodations, Expenses: AbbVie, Roche

Michael Wang

Stock and Other Ownership Interests: MoreHealth

Honoraria: Janssen Research & Development, DAVAOncology, OMI, PeerView Institute for Medical Education (PVI), OBR Oncology, Onclive, Pharmacyclics, AstraZeneca, Targeted Oncology

Consulting or Advisory Role: AstraZeneca, Janssen Research & Development, Celgene, MOREhealth, Juno Therapeutics, BioInvent International, Pharmacyclics/Janssen, Pulse Biosciences, AxImmune, Kite Pharma, Guidepoint Global, Loxo, InnoCare, Oncternal Therapeutics

Research Funding: AstraZeneca, Janssen Research & Development, Pharmacyclics, Kite Pharma, Juno Therapeutics, BeiGene, Acerta Pharma, Oncternal Therapeutics, BioInvent International, Loxo, VelosBio, Celgene, Verastem, InnoCare, Molecular Templates, Eli Lilly

Travel, Accommodations, Expenses: Janssen Research & Development, AstraZeneca, Celgene, DAVAOncology, OMI

No other potential conflicts of interest were reported.


No companion articles


DOI: 10.1200/JCO.20.02287 Journal of Clinical Oncology 38, no. 36 (December 20, 2020) 4302-4316.

Published online October 19, 2020.

PMID: 33074750

ASCO Career Center